Company Valuation: Cardiol Therapeutics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 142 43.96 71.77 151 130.4 173.5 - -
Change - -69.05% 63.28% 110.34% -13.65% 33.08% - -
Enterprise Value (EV) 1 142 43.96 36.84 120.4 108.9 158.5 163.2 173.5
Change - -69.05% -16.19% 226.78% -9.5% 45.46% 3% 6.28%
P/E -3.19x -1.41x -2.5x -3.63x -3.36x -4.18x -6.47x 41x
PBR - - 2.55x 6.18x 6.41x 8.55x 15.7x -
PEG - 0x 0.2x -0.2x 0.1x 0.54x 0.2x -0x
Capitalization / Revenue 1,803x - - - - - 52.2x 4.78x
EV / Revenue 1,803x - - - - - 49.2x 4.78x
EV / EBITDA -4.74x -1.07x -1.25x -3x -3.18x -6.73x -10.3x -8.41x
EV / EBIT -3.67x -1.06x -1.24x -2.99x -3.17x -4.52x -6.07x 36x
EV / FCF -6.03x - -1.46x -4.8x -4.56x -7.81x -34.9x -
FCF Yield -16.6% - -68.5% -20.8% -21.9% -12.8% -2.87% -
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -0.73 -0.49 -0.44 -0.51 -0.39 -0.36 -0.2325 0.0367
Distribution rate - - - - - - - -
Net sales 1 0.0788 - - - - - 3.321 36.32
EBITDA 1 -29.95 -41.12 -29.54 -40.11 -34.21 -23.54 -15.88 -20.62
EBIT 1 -38.66 -41.34 -29.79 -40.28 -34.32 -35.09 -26.87 4.821
Net income 1 -31.64 -30.93 -28.13 -36.68 -33.82 -35.21 -30.57 -8.68
Net Debt 1 - - -34.93 -30.58 -21.42 -15.01 -10.26 -
Reference price 2 2.330 0.690 1.100 1.850 1.310 1.505 1.505 1.505
Nbr of stocks (in thousands) 60,954 63,703 65,247 81,603 99,514 115,272 - -
Announcement Date 23/03/22 28/03/23 01/04/24 31/03/25 31/03/26 - - -
1CAD in Million2CAD
Estimates

P/E, Detailed evolution

P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
-4.18x - -6.73x - 122M
30.11x5.34x16.53x1.09% 43.13B
-20.5x304.3x-18.74x-.--% 34.65B
40.3x4.01x25.68x-.--% 30.03B
20.41x2.41x10.42x-.--% 28B
28.67x7.42x19.09x0.44% 24.45B
27x4.32x19.66x-.--% 13.14B
21.71x1.89x8.32x1.23% 12.53B
-20.52x13.52x-20.12x-.--% 12.25B
Average 13.67x 42.90x 6.01x 0.34% 22.03B
Weighted average by Cap. 17.38x 57.47x 8.62x 0.37%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. CRDL Stock
  4. Valuation Cardiol Therapeutics Inc.
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!